AstraZeneca Pharma India Limited
NSE: ASTRAZENMarket Closed • NSE
Day range
52 week range
AstraZeneca Pharma India Limited closed at INR5970.50 (+0.56%) on volume 0.87x its 20-day average, trading 39.38% below its 52-week high.
2026-Q1
Q1 FY2026 Financial Results
PAT moved +37.7% QoQ
2026-07-31
DIVIDEND Announced
Dividend - Rs 36 Per Share
2025-07-18
DIVIDEND Announced
Dividend - Rs 32 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.13x
Risks
Stretched Valuation: Trading at a high P/E multiple of 88.0x
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 31 Jul 2026 | Dividend | ₹36.00 / share | — | 31 Jul 2026 |
| 18 Jul 2025 | Dividend | ₹32.00 / share | — | 18 Jul 2025 |
| 05 Jul 2024 | Dividend | ₹24.00 / share | — | 05 Jul 2024 |
| 14 Jul 2023 | Dividend | ₹16.00 / share | — | 14 Jul 2023 |
| 08 Jul 2022 | Dividend | ₹8.00 / share | — | 07 Jul 2022 |
| 20 Aug 2021 | Dividend | ₹2.00 / share | — | 18 Aug 2021 |
| 21 Aug 2020 | Dividend | ₹2.00 / share | — | 20 Aug 2020 |
| 21 Aug 2019 | Dividend | ₹1.00 / share | — | 20 Aug 2019 |
| — | Annual General Meeting | Annual General Meeting | — | 30 Aug 2018 |
| — | Annual General Meeting | Annual General Meeting | — | 04 Sept 2017 |
| — | Annual General Meeting | Annual General Meeting | — | 02 Aug 2016 |
| — | Annual General Meeting | Annual General Meeting | — | 20 Aug 2015 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]
IndiaHealthcare
Is AstraZeneca Pharma India Limited Shariah compliant?
AstraZeneca Pharma India Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (0.74%) complies with AAOIFI threshold (≤ 33%).
What is AstraZeneca Pharma India Limited's current valuation relative to peers?
AstraZeneca Pharma India Limited trades at a P/E of 88.0x compared to the sector median of 37x, and a Price-to-Book of 17.1x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.13x. Interest coverage is 52x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 22.3% while net profit growth averaged consistent levels.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.